Caris Life Sciences, Inc. Common Stock CAI
i
Market dataready · fetched 2026-11-11T14:53:11.351Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T14:52:50.240705413Z
FundamentalsSEC EDGAR · ready · as of 2026-09-30 · fetched 2026-11-11T14:53:10.843721+00:00
Caris Life Sciences, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | ||||||
| 25Δ | 29.97 | 141.4% | 22.6% | |||
| 30Δ | 29.09 | 129.3% | 19.4% | 22.88 | 125.4% | 12.7% |
| 35Δ | 28.21 | 117.1% | 16.2% | 23.51 | 109.2% | 10.3% |
| 40Δ | 27.33 | 105.0% | 13.0% | 24.15 | 92.9% | 7.8% |
| 45Δ | 26.46 | 92.8% | 9.8% | 24.78 | 76.6% | 5.3% |
| 50Δ | 25.58 | 80.7% | 6.6% | |||
| 55Δ | 24.82 | 75.4% | 4.4% | |||
| 60Δ | 24.27 | 83.4% | 4.0% | |||
| 65Δ | 23.73 | 91.4% | 3.6% | |||
| 70Δ | 23.18 | 99.4% | 3.2% | |||
| 75Δ | 22.64 | 107.4% | 2.8% | |||
| 80Δ | ||||||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- 29.97
- IV
- 141.4%
- B/E move
- 22.6%
- Pseudo strike
- IV
- B/E move
30Δ
- Pseudo strike
- 29.09
- IV
- 129.3%
- B/E move
- 19.4%
- Pseudo strike
- 22.88
- IV
- 125.4%
- B/E move
- 12.7%
35Δ
- Pseudo strike
- 28.21
- IV
- 117.1%
- B/E move
- 16.2%
- Pseudo strike
- 23.51
- IV
- 109.2%
- B/E move
- 10.3%
40Δ
- Pseudo strike
- 27.33
- IV
- 105.0%
- B/E move
- 13.0%
- Pseudo strike
- 24.15
- IV
- 92.9%
- B/E move
- 7.8%
45Δ
- Pseudo strike
- 26.46
- IV
- 92.8%
- B/E move
- 9.8%
- Pseudo strike
- 24.78
- IV
- 76.6%
- B/E move
- 5.3%
50Δ
- Pseudo strike
- 25.58
- IV
- 80.7%
- B/E move
- 6.6%
- Pseudo strike
- IV
- B/E move
55Δ
- Pseudo strike
- 24.82
- IV
- 75.4%
- B/E move
- 4.4%
- Pseudo strike
- IV
- B/E move
60Δ
- Pseudo strike
- 24.27
- IV
- 83.4%
- B/E move
- 4.0%
- Pseudo strike
- IV
- B/E move
65Δ
- Pseudo strike
- 23.73
- IV
- 91.4%
- B/E move
- 3.6%
- Pseudo strike
- IV
- B/E move
70Δ
- Pseudo strike
- 23.18
- IV
- 99.4%
- B/E move
- 3.2%
- Pseudo strike
- IV
- B/E move
75Δ
- Pseudo strike
- 22.64
- IV
- 107.4%
- B/E move
- 2.8%
- Pseudo strike
- IV
- B/E move
80Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
Options history
Table
| Date | IV (%) |
|---|---|
| 73.57% | |
| 86.91% | |
| 94.96% | |
| 90.57% | |
| 75.27% | |
| 67.97% | |
| 70.17% | |
| 72.35% | |
| 72.44% | |
| 68.21% | |
| 84.51% | |
| 74.57% | |
| 77.23% | |
| 75.89% | |
| 76.96% | |
| 84.34% | |
| 80.55% | |
| 67.38% | |
| 71.14% | |
| 68.28% | |
| 66.53% | |
| 68.05% | |
| 69.31% | |
| 70.95% | |
| 72.11% | |
| 79.87% | |
| 73.63% | |
| 93.46% | |
| 91.13% | |
| 80.43% | |
| 81.23% | |
| 82.68% | |
| 80.58% | |
| 83.03% | |
| 84.90% | |
| 87.07% | |
| 81.43% | |
| 83.32% | |
| 85.53% | |
| 86.03% |
Biotechnology
CAPR
Capricor Therapeutics, Inc., a biotechnology company, focuses on the development of transformative cell- and exosome-based therapies for the treatment and prevention of a broad…
More →CBIO
Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, is focused on developing candidates for protease products in the fields of hemostasis and complement…
More →CCCC
C4 Therapeutics, Inc., a biopharmaceutical company, develops new therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer,…
More →CDXS
Codexis, Inc. discovers, develops and sells biocatalysts. The company is headquartered in Redwood City, California.
More →CELC
Celcuity Inc., a clinical-stage biotechnology company, discovers cancer subtypes and therapeutic options for cancer patients in the United States. The company is headquartered in…
More →CELU
Description unavailable
More →